Abcellera Biologics Inc (ABCL)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2025 | 12-2024 | 12-2023 | 12-2022 | 12-2021 | |
| Sales | 75,128 | 28,833 | 38,025 | 485,424 | 375,203 |
| Gross Profit | 75,128 | 28,833 | 38,025 | 485,424 | 375,203 |
| Operating Expenses | 292,231 | 343,599 | 275,232 | 268,913 | 170,790 |
| Operating Income | -217,103 | -314,766 | -237,207 | 216,511 | 204,413 |
| Other Income | 39,508 | 114,371 | 63,178 | 22,588 | 14,736 |
| Pre-tax Income | -177,595 | -200,395 | -174,029 | 239,099 | 219,149 |
| Income Tax | -31,183 | -37,538 | -27,631 | 80,580 | 65,685 |
| Net Income Continuous | -146,412 | -162,857 | -146,398 | 158,519 | 153,464 |
| Net Income | $-146,412 | $-162,857 | $-146,398 | $158,519 | $153,464 |
| EPS Basic Total Ops | -0.49 | -0.55 | -0.51 | 0.56 | 0.56 |
| EPS Basic Continuous Ops | -0.49 | -0.55 | -0.51 | 0.56 | 0.56 |
| EPS Diluted Total Ops | -0.49 | -0.55 | -0.51 | 0.50 | 0.48 |
| EPS Diluted Continuous Ops | -0.49 | -0.55 | -0.51 | 0.50 | 0.48 |
| EPS Diluted Before Non-Recurring Items | -0.49 | -0.55 | -0.51 | 0.50 | 0.48 |
| EBITDA(a) | $-188,282 | $-217,768 | $-206,313 | $249,613 | $221,663 |